Psoriasis: History, Present and Future Prospects

Order of Publishing in Issue: 
Volume :7
Issue :3
July, 2013
Page No: 
Ajay Singh and Neena Bedi*
Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar - 143005, India

Abstract :

Psoriasis is a chronic condition which causes the inflammation of the skin due to the activation of immune system leading to abnormal keratinocytes proliferation. The keratinocytes mature within a week as compared to normal cycle of 27 to 28 days. The oldest of the treatment includes the use of coal tar, Dithranol, sunlight, Dead Sea salts and emollients. Dermatologists now have a host of new treatments for psoriasis, using immunobiologics to combat this disease. The first line treatment includes topical therapy with corticosteroids and phototherapy treatment. Immunomodulators have been use as an option for second line treatment, but most of them as off label therapies. The potent candidates include calcineurin inhibitors and cytotoxic agents. Methotrexate is considered as a gold standard against which the efficacies of other biologics are being evaluated. Novel drug delivery systems are also on their way for the treatment like methotrexate niosomal gel.

psoriasis, corticosteroids, biological agents, calcineurin inhibitors, immunosuppressants
Paper-12.pdf143.72 KB

To download full text articles and issues in PDF at no cost.All you have to do is fill out a brief registration form. It's easy and it's free. At any time, you may request removal of your contact information from our database.
Click here to Register | Click here if you have already registered

2018 ABAP Awards

Invitation for Nominations to 2019 ABAP Awards
The Association of Biotechnology and Pharmacy invites nominations for the following awards from the eligible talented people with proven track record and achievements on or before August 31, 2019 in the prescribed format.



Upcoming 0 events

  • No upcoming events available

User login